Today’s Research Reports on Stocks to Watch: Celsion Corporation and Nektar Therapeutics
Shares of Nektar added more gains to its share price on Monday after it saw gains last week. The company announced positive data from a phase 1/2 study of NKT-214, its investigational cancer therapy. Shares of Celsion also blew up after the company announced it has submitted its Phase I/II clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer.
RDI Initiates Coverage on:
Celsion Corporation shares closed up 6% on Monday with a little over 6 million shares traded. The stock soared after the company announced that it has submitted its Phase I/II clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1. GEN-1 is Celsion’s DNA-based immunotherapy for the localized treatment of ovarian cancer. The company’s chief medical officer and senior vice president, Dr. Nicolas Borys, stated, "GEN-1 is designed to locally activate IL-12 production which can recruit and stimulate the patient’s immune system to attack and destroy cancer. In preclinical and multiple Phase I clinical studies performed to date, GEN-1 has demonstrated good safety and impressive immune system stimulation and clinical activity. This trial will evaluate its value as an adjuvant to current standard of care in newly diagnosed Stage III/IV ovarian cancer patients with a relatively healthy immune system. We look forward to initiating the study in the first half of 2018.”
Access RDI’s Celsion Corporation Research Report at:
Nektar Therapeutics shares closed up 14.15% yesterday and hit a new high of $41.34 during intra-day trading after the company announced this past Saturday encouraging first data from a phase 1/2 study to evaluate the company’s NKTR-214 investigational cancer therapy in conjunction with Bristol-Myers Squibb’s Opdivo. In the trial, seven of eleven patients with advanced treatment-naive stage IV melanoma responded to the combination, and 91% had either a complete response, partial response, or stable disease. Six out of 13 patients responded in the first-line advanced kidney cancer group with disease control rate at 85%. In 3 out of 4 patients responded in the non-small-cell lung cancer group. Trading volume was nearly 17.5 million shares compared to an average of just under 1.3 million shares. The stock was one of the best performers on the NASDAQ on Monday.
Access RDI’s Nektar Therapeutics Research Report at:
Our Actionable Research on Celsion Corporation (NASDAQ: CLSN) and Nektar Therapeutics (NASDAQ: NKTR) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.